

Company Fact Sheet

Headquarters:

25841 Industrial Blvd. Suite 275
Hayward, CA 94545
USA
+1 650.239.9070

Number of Employees:

265+

RefleXion Medical:

A privately held therapeutic oncology company founded in 2009 by Sam Mazin, Ph.D. and Akshay Nanduri to create a new cancer treatment through biological guidance for the treatment of localized and metastatic cancer.

Technology:

Granted Breakthrough Device Designation for lung tumors and marketing clearance under the De Novo pathway by the FDA, the **RefleXion® X1 machine with SCINTIX™ biology-guided radiotherapy (BgRT)** is designed to expand radiotherapy from single tumor to multiple tumor treatment for **primary and metastatic lung or bone tumors, while also minimizing the delivery of radiation to vital, healthy tissue.**

SCINTIX therapy is delivered through the RefleXion X1 machine, which combines positron emission tomography (PET) with a linear accelerator (LINAC) to deliver a radiation dose that tracks the cancer's motion. SCINTIX technology is the first and only radiotherapy approach that uses a single radiotracer injection to transform cancer cells into real-time biological guides that steer radiotherapy delivery to the tumor.

The innovative technology represents a significant advance in cancer treatment for patients by leveraging a proven modality for visualizing cancer with one of the most effective ways to treat cancer, thereby fundamentally altering the cancer treatment model.

Funding & Investors:

RefleXion has raised \$585M in debt and equity funding. The company is backed by TPG Growth/The Rise Fund, Ascension Ventures, Catalio, PSP Investments, Ally Bridge Group, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, and global pharmaceutical leaders Pfizer Ventures, and Johnson & Johnson Innovation – JJDC, Inc. The company has also received grant funding from the National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Program.

Media Resources:

Todd Powell, president, CEO
Sam Mazin, Ph.D., founder, CTO
Steve Schoch, CFO
Sean Shirvani, M.D., CMO
Judy Bartlett-Roberto, VP, marketing